VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,096,453 | +5.1% | 1,943,830 | +3.0% | 0.04% | +10.5% |
| Q2 2023 | $94,292,014 | +2917.0% | 1,888,106 | +2164.2% | 0.04% | +3700.0% |
| Q1 2023 | $3,125,382 | -11.5% | 83,388 | +13.2% | 0.00% | -50.0% |
| Q4 2022 | $3,533,340 | +225.7% | 73,688 | +63.0% | 0.00% | +100.0% |
| Q3 2022 | $1,085,000 | +10.3% | 45,200 | 0.0% | 0.00% | – |
| Q2 2022 | $984,000 | -7.4% | 45,200 | +2.7% | 0.00% | – |
| Q1 2022 | $1,063,000 | +20.4% | 44,000 | +18.6% | 0.00% | – |
| Q4 2021 | $883,000 | -6.2% | 37,100 | 0.0% | 0.00% | – |
| Q3 2021 | $941,000 | +38.4% | 37,100 | +22.8% | 0.00% | – |
| Q2 2021 | $680,000 | +53.8% | 30,200 | +34.8% | 0.00% | – |
| Q1 2021 | $442,000 | -36.9% | 22,400 | -15.2% | 0.00% | – |
| Q4 2020 | $701,000 | -46.2% | 26,400 | 0.0% | 0.00% | -100.0% |
| Q3 2020 | $1,304,000 | – | 26,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $99,174,000 | 24.03% |
| Medicxi Ventures Management (Jersey) Ltd | 1,887,478 | $44,903,000 | 11.24% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,111,485 | $26,442,000 | 11.06% |
| FRAZIER MANAGEMENT LLC | 2,309,554 | $54,944,000 | 4.23% |
| Kynam Capital Management, LP | 211,483 | $5,031,000 | 2.69% |
| GREAT POINT PARTNERS LLC | 500,000 | $11,895,000 | 2.64% |
| Ghost Tree Capital, LLC | 250,000 | $5,948,000 | 2.13% |
| RA Capital Management | 4,240,464 | $100,881,000 | 1.78% |
| Opaleye Management Inc. | 315,800 | $7,513,000 | 1.59% |
| Ikarian Capital, LLC | 295,111 | $7,021,000 | 1.05% |